Fact CheckerSign in

NCT05429515Not yet recruitingPhase 4

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury: a Prospective Cohort Study

Source: ClinicalTrials.gov · Last updated 23 Jun 2022 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

In patients with multiple myeloma-related acute kidney injury, compare the renal outcome of chemotherapy combined with HFR-SUPRA to chemotherapy combined with hemodialysis.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
50 (estimated)
First submitted
19 Jun 2022
Start date
1 Jul 2022
Primary completion date
1 Jul 2032
Lead sponsor
Peking Union Medical College Hospital
NCT number
NCT05429515

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 50
  • From 1 Jul 2022 to the primary completion date, 1 Jul 2032
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • active bleeding
  • other malignant tumor
  • conditions not suitable to participate in the study, such as bad compliance

Lab values

  • chronic kidney disease stage 3 to 5 (eGFR\< 60 ml/min/1.73m2 for at least 3 months)

Other

  • haemodynamics unstability
  • cardiovascular and cerebrovascular events in the last month

Who the study is looking for

  • 18 to 80 years old
  • new onset of multiple myeloma
  • acute kidney injury with eGFR \< 15 ml/min/1.73m2 and need hemodialysis
  • biopsy-proven cast nephropathy or clinical diagnosis of cast nephropathy based on exclusion of other causes of acute kidney injury including post-renal obstruction, hypercalcaemia, amyloidosis, light-chain deposition disease, contrast media and drug nephropathy
  • serum light chain \> 500 mg/L

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.